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Background: Insulin resistance (IR) and endothelial dysfunction are frequently associated in cardiac disease.
The T−786→C variant in the promoter region of the endothelial nitric oxide synthase (eNOS) gene has been
associated with IR in both non-diabetic and diabetic subjects. Aim of the study was to assess the reciprocal
relationships between T−786→C eNOS polymorphism and IR in ischemic and non-ischemic cardiomyopathy.
Method: A group of 132 patients (108 males, median age 65 years) with global left ventricular (LV) dysfunction
secondary to ischemic or non-ischemic heart disease was enrolled. Genotyping of T−786→C eNOS gene promoter,
fasting glucose, insulin, and insulin resistance (defined as HOMA-IR index > 2.5) were determined in all patients.
Results: Genotyping analysis yielded 37 patients homozygous for the T allele (TT), 70 heterozygotes (TC) and
25 homozygous for C (CC). Patients with CC genotype had significantly higher systemic arterial pressure, blood
glucose, plasma insulin and HOMA index levels than TT. At multivariate logistic analysis, the history of hypertension
and the genotype were the only predictors of IR. In particular, CC genotype increased the risk of IR (CI% 1.4-15.0,
p < 0.01) 4.5-fold. The only parameter independently associated with the extent of LV dysfunction and the
presence of heart failure (HF) was the HOMA index (2.4 CI% 1.1-5.6, p < 0.04).
Conclusions: T−786→C eNOS polymorphism was the major independent determinant of IR in a population of
patients with ischemic and non-ischemic cardiomyopathy. The results suggest that a condition of primitive eNOS
lower expression can predispose to an impairment of glucose homeostasis, which in turn is able to affect the
severity of heart disease.
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Insulin resistance (IR) is a common condition in patients
with both ischemic and non-ischemic cardiomyopathy.
It may be secondary to heart failure (HF) syndrome but
also contributes to the disease [1-3]. As IR represents
a potentially reversible alteration, its early identifica-
tion may have a crucial role in HF prevention and treat-
ment [4,5].* Correspondence: vecoli@ifc.cnr.it
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reproduction in any medium, provided the orInsulin resistance has often been linked to endo-
thelial dysfunction, defined as paradoxical or inadequate
endothelial-mediated vasodilation [6-8]. Specifically, IR
has been associated with the decreased synthesis and/or
release of nitric oxide (NO), as occurs in many clinical
conditions including HF, or with its exaggerated con-
sumption due to high tissue levels of reactive oxygen
and nitrogen species in a condition of altered glucose
and lipid metabolism [7]. Alternatively, genetically deter-
mined deficiency of endothelial-derived NO could pre-
dispose to IR. In an experimental study, Duplain et al.
showed that knockout mice for the endothelial NOtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tensive, suggesting that eNOS is important not only for
cardiovascular control but also for glucose homeostasis
[9]. In humans, a thymidine-to-cytosine (T to C) transi-
tion mutation (T−786→C) in the promoter region of the
gene has been associated with reduced eNOS expression
[10] and has been linked to IR both in non-diabetic
subjects and Type 2 diabetic patients [11,12].
Based on these premises, we hypothesized that genetic
eNOS impairment could be an independent determin-
ant of IR in patients with HF. Accordingly, in the
present study we tested the reciprocal relationships
between T−786→C eNOS polymorphism and IR in
patients with ischemic and non-ischemic cardiomyop-




The study population consisted of 132 patients (108
males; age 65.5 ± 10.4 years) with mild to severe left ven-
tricle (LV) systolic dysfunction with or without HF
(NYHA Class I-III). Sixty-six patients had ischemic, while
66 patients had non-ischemic LV dysfunction (angiogra-
phically normal coronary arteries). The population was
selected among 498 consecutive patients referred for
elective coronary angiography at CNR Institute of Clinical
Physiology from 2007 to 2010 and enrolled in the GENO-
COR ( Genetic Mapping for Assessment of Cardiovas-
cular Risk) study (FIRB 2005) aimed to assess genetic
determinants of coronary artery disease. Selection criteria
included: 1.reduced LV ejection fraction (EF) (< 50%) by
the biplane area-length method on rest echocardiography;
2. optimal medical treatment with no changes in medica-
tion during the last 3 months; 3. no evidence of recent
myocardial infarction or unstable angina (within the last 6
months); 4. absence of acute or unstable HF; 5. no history
of diabetes; 6. no significant concomitant disease such
as infections, malignancies or connective tissue disease;
7. informed written consent. A complete clinical history
was collected from all patients. The following cardiovas-
cular risk factors were recorded in every patient: age, sex,
smoking habit (current smokers or ex-smokers – within
the last year), hypercholesterolemia (total cholesterol level
≥ 200 mg/dl, low-density lipoprotein [LDL] cholesterol
level ≥ 100 mg/dl or treatment with lipid-lowering
agents), history of arterial hypertension (arterial blood
pressure ≥ 140 mmHg for systolic or ≥ 90 mmHg for dia-
stolic, or use of anti-hypertensive medications), and obes-
ity (body mass index ≥ 30 kg/m2). Severe LV dysfunction
with heart failure (LVEF < 40% and NYHA Class II-III)
was present in 35 patients.
Ninety-eight healthy volunteers (46 males; age 45.1 ±
9.5 years), members of the medical and technical staff ofour Institution, negative for clinical cardiovascular risk
factors, were used as control group in order to compare
the frequency of T−786→C genotypes in the general
population relative to patients.
The Local Ethics Committee (Comitato Etico Speri-
mentazione Farmaco - Azienda Ospedaliera Universi-
taria Pisana, Italy) approved the study and all patients
gave their written informed consent. The research was
conducted according to the principle of the Declaration
of Helsinki
Biohumoral characterization
Fasting plasma glucose, fasting serum insulin concentra-
tions and homeostasis model assessment [HOMA] score
were measured in all patients. Blood samples were
obtained from each subject after a 12-h overnight fast by
evacuation from an antecubital vein into vacutainer
tubes. Fasting plasma glucose concentration was mea-
sured by a glucose oxidase method, and concentrations
of total cholesterol and triglycerides were measured by
enzymatic procedures using an autoanalyzer (UniCel
DxC 600, Beckman Coulter). Fasting insulin concentra-
tion was measured by immunoassay (Architect i1000 sr,
Ilex Medical). Insulin resistance was defined as Homeo-
stasis Model Assessment of IR (HOMA-IR) > 2.5. The
HOMA-IR was calculated from the formula: HOMA-IR =
fasting serum insulin (μU/ml) x fasting plasma glucose
(mmol/l)/22.5 [13].
Analysis of T−786→C polymorphism in the 5’- flanking
region of the eNOS gene
The presence of the T-C conversion at nucleotide pos-
ition 786 in the 5’-flanking region of the eNOS gene
was determined by PCR amplification with the primers
5’- ATGCTCCCACCAGGGCATCA-3’ (sense) and 5’-
GTCCTTGAGTCTGACATTAGGG- 3’ (antisense), as
previously reported [14]. The 236-bp PCR fragments
were digested with NgOAIV restriction enzyme for 16 h
at 37 °C. The wild-type allele (T) has no NgOAIV cleav-
age site, whereas the PCR product is cleaved into
two fragments of 203 and 33 bp in the presence of the
C-786 allele.
Statistical analysis
Statistical analyses of the data were conducted with the
Statview statistical package, version 5.0.1 (Abacus Con-
cepts, Berkeley, Calif., USA). Data are expressed as
mean ± SD. Because of the skewness of the distributions
of biochemical values, analyses have been performed
using the logarithmic transformation of data. Differences
between the means of two continuous variables were
evaluated by Student's t-test. Differences in non-
continuous variables and genotype distribution were
tested by χ2 analysis. The data for three or more
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ance, and significant differences among pairs of means
were tested by Bonferroni’s test. Regression analysis with
Pearson’s test was also used to evaluate the relationship
between the continuous variables. Unconditional logistic
regression was used to calculate odds ratio (ORs) and
95% CIs. The ORs were also adjusted for other risk
factors. A p-value < 0.05 was considered significant.
Assuming a mean value of HOMA of 2.0 and standard
deviation of 2.5, a study with a sample size of 130 patients
would be needed to detect a 15 % difference or more in
HOMA-IR between the heterozygous and the TT homo-
zygous patients for T−786→C variant, with a power of
β =80% by means of a two-sided t-test with α = 5%.
Results
Genotype analysis
Genotyping analysis in the patient population yielded 37
patients homozygous for the T−786 allele (TT), 70 het-
erozygotes (TC) and 25 homozygous for C-786 (CC). The
genotype distribution of the T−786→C polymorphism
in patients was not significantly different from that
observed in the control group (Figure 1a) and was com-
parable with that previously observed in Caucasian sub-
jects [14]. Nevertheless, when patients were stratified by
HOMA-IR index (HOMA-IR index > or < 2.5), the
allelic distribution was significantly different. The fre-
quency of CC homozygous patients was significantly
higher and that of TT homozygous patients was signifi-
cantly lower in patients with HOMA-IR index > 2.5 as
compared to patients with HOMA-IR index < 2.5 (25.8%
vs 13.5%, p < 0.05 and 19.8 vs 35.1, p <0.05) (Figure 1b).
Clinical and biochemical evaluation
The demographic and clinical characteristics of the
patients population are shown in Table 1. Stratifying theFigure 1 Genotype frequencies for the polymorphism of eNOS gene
systolic LV dysfunction and b) in patients with HOMA-IR index < 2.5 opopulation according to eNOS T−786→C polymorphism,
the three groups of patients did not differ as to age, sex,
smoking, family history of coronary artery disease
(CAD), obesity and systemic lipid metabolism. The three
groups also did not differ as to etiology and severity of
LV dysfunction or presence of overt HF. Conversely, sig-
nificant differences were found in arterial hypertension
and in glucose homeostasis. Indeed, a history of arterial
hypertension was more frequent in CC than in TT
patients. Blood glucose and insulin levels were signifi-
cantly different within the three groups with an increas-
ing trend from TT to CC patients (Figure 2). As a
consequence, CC patients had higher values of HOMA-
IR index compared with TC and TT patients (3.9 ± 2.8
CC vs 2.4 ±2.8 TC vs 2.2 ± 1.3 TT) and a greater preva-
lence of subjects with HOMA-IR index > 2.5 (60% com-
pared with 30% in the TT group, p = 0.008).
Determinants of IR
At univariate analysis, including CV risk factors, LV
functional parameters and eNOS T−786→C polymorph-
ism, the presence of IR (as defined by a HOMA index
> 2.5) was associated with history of hypertension, pres-
ence of a more severe LV dysfunction with HF and
the eNOS genotype (Table 2). However, at multivariate
logistic analysis (Table 2), the history of hypertension
(p = 0.03) and the genotype remained the only inde-
pendent predictors of IR (Table 2). In particular, the
presence of TC genotype was associated with 2.1-fold
(CI% 1.0-5.7, p < 0.05) higher risk of IR while the
mutated genotype (CC) increased the risk to 3.3 times
(CI% 1.1-10.1, p = 0.03) after correction for all other
factors. Conversely, in the same population, the presence
of severe LV dysfunction with HF was predicted at both
univariate and multivariate analysis only by the HOMA
index value (2.4 CI% 1.1-5.5, p = 0.03) (Table 3).promoter T−786→C a) in healthy subjects and patients with
r with HOMA-IR > 2.5.
Table 1 Demographic and clinical characteristics of study population
Whole Population n =132 TT n=37 TC n=70 CC n=25 p-value TT vs CC
Mean age (mean ± SD) 65.4±10.4 64.3 ± 12.1 65.5 ± 10.0 67.1 ± 9.0 ns
Gender (male), n (%) 108 (81.8) 32 (86.5) 57 (81.4) 19 (82.6) ns
Smoking habit, n (%) 77 (58.3) 19 (51.4) 46 (45.7) 10 (43.5) ns
Hypercholesterolemia n (%) 73 (55.3) 14 (37.8) 46 (65.7) 11 (47.8) ns
History of Hypertension, n (%) 45 (34.1) 9 (24.3) 25 (35.7) 9 (39.1) < 0.05
CAD Familiarity, n (%) 56 (42.4) 19 (51.4) 46 (65.7) 10 (43.5) ns
Obesity, n (%) 20 (15.2) 9 (2.4) 9 (1.3) 2 (0.9) ns
DCM Etiology, n (%) 21 (32) 32 (48) 13 (20) ns
IHD Etiology, n (%) 16 (24) 38 (58) 12 (18) ns
LV Ejection Fraction, % 37.7 ± 7.6 38.2 ± 8.4 38.0 ± 7.1 36.4 ± 7.9 ns
LVEF<40% & NYHA Class II-III 35 (26.5) 8 (22.8) 18 (51.4) 9 (25.7) ns
Glucose (mg/dL) ±SD 102.5 ± 23.4 95.5 ± 10.6 102.1 ± 25.3 114.2 ± 27.7 0.001
Insulin (mU/mL) ±SD 11.1 ± 7.3 9.5 ± 4.8 11.3 ± 8.3 12.9 ± 7.4 0.04
HOMA-IR ±SD 2.9 ± 2.5 2.2 ± 1.3 2.3 ± 2.8 3.9 ± 2.8 0.005
HOMA index>2.5, n (%) 58 (43.9) 11 (30.0) 32 (45.7) 15 (60) 0.008
Total Cholesterol (mg/dL) ±SD 185.7 ± 41.3 179.4 ± 34.0 188.3 ± 44.3 187.8 ± 42.4 ns
HDL-Cholesterol (mg/dL) ±SD 42.3 ± 11.9 41.2 ± 10.9 42.2 ± 13.2 44.4 ± 10.1 ns
LDL-Cholesterol (mg/dL) ±SD 118.4 ± 36.0 116.8 ± 29.1 120.2 ± 36.5 115.9 ± 44.1 ns
Triglycerides(mg/dL) ±SD 123.8 ± 82.5 107.4 ± 54.2 127.7 ± 74.2 137.4 ± 127.3 ns
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This study provides evidence that the T−786→C poly-
morphism in the promoter region of eNOS gene is the
major independent determinant of IR in patients with
both ischemic and non- ischemic cardiomyopathy. Inter-
estingly, among all classic cardiovascular risk factors,
IR is the only one independently associated with the
extent of LV dysfunction and the presence of HF in this
population. Taken together, our results suggest that
in either ischemic or non- ischemic cardiomyopathy,
IR may occur preferentially in patients with a genetic
predisposition to endothelial dysfunction (eNOS geneFigure 2 Effects of the eNOS gene promoter T−786→C polymorphism
dysfunction. *p=0.005 CC vs TT; #p<0.05 CC vs TT.polymorphism) and may worsen the severity of the
cardiac disease. Specifically, the mutual order among
(genetically determined) endothelial dysfunction, IR and
LV dysfunction was found independently of etiology of
cardiac disease.
A link between insulin homeostasis and endothelial
function has been long documented [6-8]. Endothelial
function is modulated by insulin through the stimulatory
effects of the hormone on NO production [6,8]. Nitric
oxide is synthesized from L-arginine by a family of
enzymes called NO synthases (NOSs). The constitutively
expressed eNOS gene, which maps on the 7q35–36on glucose and insulin levels in patients with systolic LV
Table 2 Predictors of HOMA-IR at univariate and multivariate analysis by logistic regression
Variables Univariate Analysis Multivariate Analysis
OR (CI 95%) p-value OR (CI 95%) p-value
Age 0.9 (0.9-1.0) 0.6 1.0 (0.9-1.0) 0.4
Male sex 1.7 (0.7-4.3) 0.2 2.7 (0.9-7.9) 0.07
Smoking habit, n (%) 0.7 (0.3-1.4) 0.3 _ _
Hypercholesterolemia n (%) 0.7 (0.4-1.5) 0.4 _ _
History of Hypertension, n (%) 1.9 (0.8-3.7) 0.07 2.0 (0.9-4.6) 0.09
CAD Familiarity, n (%) 0.6 (0.3-1.3) 0.2 _ _
Obesity, n (%) 0.9 (0.4-2.4) 0.9 _ _
Non-ischemic Etiology 1.8 (0.9-3.7) 0.08 1.9 (0.9-4.5) 0.1
TC genotype 2.1 (0.9-5.0) 0.08 2.4 (1.0-5.8) 0.06
CC genotype 3.6 (1.3-10.7) 0.01 3.9 (1.3-12.7) 0.02
LV Ejection Fraction, % 0.9 (0.9-1.0) 0.1 1.0 (0.9-1.0) 0.9
LVEF<40% & NYHA Class II-III 2.4 (1.1-5.4) 0.03 2.0 (0.7-5.8) 0.2
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has been shown that eNOS activity is modulated by in-
sulin through a series of phosphorylations triggered by
the hormone binding with its receptor on the endothe-
lial cell membrane. Specifically, the insulin signaling cas-
cade leads to a specific phosphorylation of eNOS that
increases the enzyme activity [8].
Nevertheless, some experimental data suggest that pri-
mary abnormalities of eNOS function may influence in-
sulin homeostasis. In fact, eNOS knockout mice have
been reported to be hypertensive and insulin resistant
[9,15,16]. One elegant study in a mouse model of eNOS
partial knockout showed that the partial deletion of
the gene does not alter per se insulin sensitivity and
blood pressure. However, when challenged with nutri-
tional stress, partial eNOS deficiency facilitates the de-
velopment of IR and arterial hypertension, providing
further evidence for the importance of this gene in pre-
disposing to glycometabolic and vascular abnormalities




Male sex 1.5 (0.5-4.3)
Smoking habit, n (%) 0.9 (0.4-2.0)
Hypercholesterolemia n (%) 0.9 (0.4-2.0)
History of Hypertension, n (%) 0.7 (0.3-1.6)
CAD Familiarity, n (%) 0.5 (0.2-1.2)
Obesity, n (%) 1.9 (0.7-5.1)
TC genotype 1.3 (0.5-3.4)
CC genotype 1.8 (0.6-6.5)
HOMA index 2.3 (1.0-5.2)between eNOS gene expression, hypertension and insu-
lin resistance are unavailable. Likewise, the mechanisms
by which the primitive endothelial alteration can affect
glucose homeostasis and systemic blood pressure are not
fully known.
In keeping with the above experimental findings, in a
population of patients with ischemic and non-ischemic
cardiac disease, we found a clear correlation between
eNOS gene promoter polymorphism, the occurrence
of an insulin-resistant phenotype and the presence of
arterial systemic hypertension. Given the location of
-786T>C in the promoter region of the eNOS gene, it
may affect eNOS expression levels. Actually, lower
eNOS mRNA and serum nitrite/nitrate levels have been
found in individuals with the -786C variant [9], and
reporter gene studies have supported this functional
role [18,19].
One possible hypothesis linking the primitive impair-
ment of eNOS function with insulin resistance states
that endothelial dysfunction causing systemic NOiate and multivariate analysis by logistic regression
lysis Multivariate Analysis
p-value OR (CI 95%) p-value
0.1 1.0 (0.9-1.1) 0.1








<0.05 2.4 (1.1-5.4) 0.03
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decrease in blood flow to the myocardium and muscles.
This in turn may reduce myocardial and muscular
glucose uptake. As a result, high glucose levels in the
blood stimulate insulin secretion and in the long run
may cause IR and diabetes. Therefore, a genetic variation
that affects NO regulation may contribute to both alter-
ation in vascular tone and to IR. Consistent with this
hypothesis, few clinical studies have shown a significant
association between that T−786→C polymorphism in the
promoter region of the eNOS gene and IR in both non-
diabetic subjects and Type 2 diabetic patients [11,12].
In this framework, our study confirms and extends pre-
vious results in patients without known diabetes but
with systolic LV dysfunction.
An additional finding of the present study was that
in our population IR, which occurred preferentially in
subjects with eNOS gene polymorphism, was also an
independent determinant of a more severe cardiac
dysfunction with HF, irrespective of etiology. A recent
study showed that the T−786→C promoter polymorph-
ism was specifically associated with a significant reduc-
tion in eNOS mRNA expression in myocardial tissue
obtained from failing human myocardium, while a differ-
ent eNOS polymorphism G(894)–>T of exon 7 was not.
The authors concluded that the reduced eNOS expres-
sion associated with the promoter gene polymorphism
might be involved in the pathogenesis of cardiac failure
[12]. Our findings did not discover a direct relationship
between eNOS polymorphism and the severity of LV
dysfunction; however, these conditions were linked by
the presence of IR.
Insulin resistance, often manifested clinically through
the feature of the metabolic syndrome or type 2 diabetes
mellitus, has reached epidemic levels in many nations
throughout the world [5,20]. Furthermore the presence
of diabetes mellitus is more than 7 times as potent risk
factor for mortality in the non-ischemic and ischemic
cardiomyopathy population [21]. Certainly, the eNOS
defective gene cannot be the only cause leading to insulin
resistance and cardiovascular damage. Rather, our results
suggest that this condition might create an individual sub-
strate where the addition of other common factors (such
as high fat diet or altered lipid profile) is poorly tolerated
and enough to predispose to development of insulin
resistance and more severe cardiac damage.
Our study findings should be interpreted bearing in
mind some limitations. Firstly, we acknowledge that our
sample size may temper statistical estimations in some
categories. Secondly, genetic and acquired factors able to
condition the presence and the extent of cardiac damage
and the development of HF in different individuals are
multiple and interactions are complex. Accordingly,
adequate experimental models and large longitudinalclinical studies are needed to better elucidate the patho-
genetic and prognostic relevance of these observations.
Conclusion
Nevertheless, this study first shows a clear link between
a genetic endothelial dysfunction and abnormalities in
glycometabolic profile in patients with both ischemic and
non-ischemic cardiomyopathy. Confirming the impact of
a defective eNOS gene in the development of IR and HF
will have major clinical relevance for identifying subjects
at higher risk among patients with cardiac dysfunction.
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